Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K, Wilding JPH, Garcia Rodriguez LA, Cea-Soriano L, Kohsaka S, Nicolucci A, Lucisano G, Lin FJ, Wang CY, Wittbrodt E, Fenici P, Kosiborod M.
Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35. doi: 10.1016/S2213-8587(19)30384-5.
Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan.
Tangri N, Rastogi A, Nekeman-Nan C, Hong LS, Ozaki A, Franzén S, Sofue T.
Adv Ther. 2024 Mar;41(3):1151-1167. doi: 10.1007/s12325-023-02773-x. Epub 2024 Jan 19.
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.
J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.
Association of glomerular filtration rate slope with timely creation of vascular access in incident hemodialysis.
Lim LM, Lin MY, Hwang SJ, Chen HC, Chiu YW.
Sci Rep. 2021 Jun 23;11(1):13137. doi: 10.1038/s41598-021-92359-w.
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, Yarden A, Khazim K, Shehadeh N, Melzer Cohen C.
Diabetes Obes Metab. 2024 Aug;26(8):3058-3067. doi: 10.1111/dom.15623. Epub 2024 Apr 28.
Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.
Kawano R, Haze T, Fujiwara A, Haruna A, Ozawa M, Kobayashi Y, Saka S, Hirawa N, Tamura K.
Clin Exp Nephrol. 2024 Jul 6. doi: 10.1007/s10157-024-02532-4. Online ahead of print.
Initial slope technique for estimation of the apparent volume of distribution during constant-rate intravenous infusion.
Cocchetto JF, Cocchetto DM, Bjornsson TD, Bergan T.
J Pharm Sci. 1984 Jan;73(1):58-62. doi: 10.1002/jps.2600730115.
The slope of the initial temperature drop predicts acute pulmonary vein isolation using the second-generation cryoballoon.
Deubner N, Greiss H, Akkaya E, Zaltsberg S, Hain A, Berkowitsch A, Güttler N, Kuniss M, Neumann T.
Europace. 2017 Sep 1;19(9):1470-1477. doi: 10.1093/europace/euw192.
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.
Hopkin RJ, Cabrera GH, Jefferies JL, Yang M, Ponce E, Brand E, Feldt-Rasmussen U, Germain DP, Guffon N, Jovanovic A, Kantola I, Karaa A, Martins AM, Tøndel C, Wilcox WR, Yoo HW, Burlina AP, Mauer M.
Mol Genet Metab. 2023 Feb;138(2):106967. doi: 10.1016/j.ymgme.2022.106967. Epub 2022 Nov 30.
Dietary restriction, mortality trajectories, risk and damage.
Partridge L, Pletcher SD, Mair W.
Mech Ageing Dev. 2005 Jan;126(1):35-41. doi: 10.1016/j.mad.2004.09.017.
